Chronic kidney disease
Conditions
Interventions
Theranova group:Use Theranova 400 for 1 week of mid week hemodialysis treatment
HDF group:Use HDF for one week of mid week hemodialysis treatment
Sponsors
the First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged >18 years old and 1.2 in the last 2 evaluations, and the last Kt/V evaluation was performed within 4 weeks before study screening or during study screening.
Exclusion criteria
Exclusion criteria: 1) Patients with acute kidney injury with potential for recovery; 2) Pregnant or lactating women; 3) Patients diagnosed with New York Heart Association (NYHA) Class IV congestive heart failure, or acute coronary syndrome and/or myocardial infarction within the past 3 months prior to study initiation; 4) Patients known to have hemodynamic instability, anemia (hemoglobin 130 g/L with coagulation risk; 5) Patients judged by the investigator to have active or persistent infection (e.g., patients with C-reactive protein [CRP] levels exceeding five times the upper limit of normal); 6) Patients with severe malnutrition or severe diseases affecting liver function (e.g., serum albumin <30 g/L); 7) Diagnosed with hepatitis B surface antigen (HBsAg) positive, hepatitis C antibody (HCV-Ab) positive, with assessment by the investigator of advanced liver or pulmonary disease; 8) Patients diagnosed with human immunodeficiency virus (HIV) and positive for syphilis; 9) Patients receiving immunosuppressive therapy or with autoimmune diseases; 10) Patients with a history of solid tumors, receiving or anticipated to receive anticancer therapy in the past or next 6 months, or with an expected lifespan <1 year, or with a history of hematologic malignancy; 11) Patients with planned living kidney donation or considering switching to peritoneal dialysis (PD) or requesting single-needle dialysis within the next year; 12) Patients with allergies to polyarylethersulfone (PAES) or polysulfone (PS) membranes or poor tolerance to synthetic dialysis membranes; 13) Patients with a history of severe mental disorders unable to provide consent or comply with study procedures; 14) Currently participating in or having participated in other interventional clinical trials within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| XFLC RR;ß2-MG RR;C-reactive protein, CRP;Transcriptome sequencing data of peripheral blood total RNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Kt/V;URR;YKL-40 RR; | — |
Countries
China
Contacts
Public ContactHuang Ying
the First Affiliated Hospital of Soochow University
Outcome results
None listed